38.34
price up icon0.84%   0.32
after-market Dopo l'orario di chiusura: 36.62 -1.72 -4.49%
loading

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

pulisher
08:58 AM

BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN

08:58 AM
pulisher
08:50 AM

BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance

08:50 AM
pulisher
Jun 04, 2025

BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan

May 19, 2025
pulisher
May 15, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

May 15, 2025
pulisher
May 14, 2025

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN

May 14, 2025
pulisher
May 14, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo

May 14, 2025
pulisher
May 14, 2025

Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com

May 14, 2025
pulisher
May 14, 2025

BridgeBio Expands Team with 101,974 Shares in RSU Grants to 36 New Biotech Talents - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus

May 12, 2025
pulisher
May 12, 2025

BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times

May 12, 2025
pulisher
May 11, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

May 11, 2025
pulisher
May 10, 2025

(BBIO) Trading Report - news.stocktradersdaily.com

May 10, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 10, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Recursion cuts nearly half of its pipeline - statnews.com

May 06, 2025
pulisher
May 05, 2025

Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com

May 05, 2025
pulisher
May 03, 2025

Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

May 03, 2025
pulisher
May 02, 2025

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga

May 02, 2025
pulisher
May 02, 2025

BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN

May 02, 2025
pulisher
May 02, 2025

BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO St - GuruFocus

May 02, 2025
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Capitalizzazione:     |  Volume (24 ore):